U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 31 - 40 of 7099 results

Status:
Investigational
Source:
INN:NAFOMINE [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Nafomine is the muscle relaxant. It was tested on lower extremity spasms in spinal cord injuries.
Status:
Investigational
Source:
JAN:PANTOTHENYL ETHYLETHER [JAN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Panthenyl ethyl ether is used in cosmetic as an antistatic and hair conditioning. However, it was found that in patients with psoriasis panthenyl ethyl ether could cause allergic contact dermatitis.
Status:
Investigational
Source:
INN:oxapropanium iodide
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Oxapropanium was studied as a cholinergic agent. Information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:BEXLOSTERIDE [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

LY 300502 is now called bexlosteride was developed as an inhibitor of the human-specific type I-selective steroid 5alpha-reductase. This drug was studied for patients with prostate cancer, however, has never been marketed.
Status:
Investigational
Source:
NCT00124696: Phase 1 Cocaine-Related Disorders
(2002)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cocaethylene is the ethyl ester of benzoylecgonine. Cocaethylene is formed in the liver after concurrent use of cocaine and alcohol. Cocaethylene works by blocking the dopamine transporter on dopaminergic presynaptic nerve terminals in the brain. It increases dopamine synaptic content, provoking enhanced postsynaptic receptor stimulation, resulting in euphoria, reinforcement, and self-administration. Compared to cocaine, which is a methyl ether of benzoylecgonine, cocaethylene has three to five times larger half-life in plasma. Cocaethylene is associated with seizures, liver damage and compromised the functioning of the immune system. It carries an 18-25 fold increase in risk for immediate death compared to cocaine alone.
Status:
Investigational
Source:
INN:duazomycin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Duazomycin (N-acetyl-DON) is one of the few naturally occurring compounds containing an aliphatic alpha diazoketo group, and is produced by Streptomyces ambofaciens. It is a derivative of 6-diazo-5-oxo-L-norleucine (DON) which was initially isolated from an unidentified Streptomyces species and which is produced together with N-acetyl-DON and duazomycin B (azotomycin) by S. ambofaciens. Duazomycin inhibited purine biosynthesis and caused accumulation of phosphoribosyl-N-formylglycineamide (FGAR) at low levels of inhibitor; higher levels blocked the synthesis of FGAR, indicating that the antibiotic behaved essentially like DON. Duazomycin is readily deacetylated by mammalian acylase to DON. As a glutamine antagonist, duazomycin was used in combination with azathioprine for the treatment of patients with advanced Wegener’s granulomatosis with renal involvement. Prolonged survival, remission of systemic signs and symptoms, roentogenologic improvement of pulmonary lesions, reduction in proteinuria and arrest of progression of renal insufficiency were observed.
Status:
Investigational
Source:
INN:nocloprost
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Nocloprost is a stable prostaglandin E2 analog with gastroprotective and ulcer-healing properties. It shows very high gastroprotective potency, relatively weak gastric inhibitory activity, and low systemic bioavailability after oral administration. Schering AG have discontinued development of the drug, which was in phase II clinical trials for the treatment of peptic ulcer.
Status:
Investigational
Source:
INN:pirodavir
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Pirodavir (R77975) (ethyl 4-[2-(1-[6-methyl-3-pyridazinyl]-4-piperidinyl)ethoxy]benzoate) and its predecessor (R61837) belong to a series of pyridazine analogues developed by the Janssen Research Foundation. Compared to R61837, pirodavir was 500-fold more potent as an antiviral in vitro, inhibiting 80% of 100 rhinovirus serotypes tested at concentration of 0.064 mg/mL or less. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication. The mode of action appears to be serotype specific, since pirodavir was able to inhibit the adsorption of human rhinovirus 9 but not that of human rhinovirus 1A. Pirodavir is a novel capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes.
Status:
Investigational
Source:
INN:PAMAQUESIDE [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Pamaqueside, an 11-ketotigogenin cellobioside was developed as a cholesterol absorption inhibitor for the treatment of hypercholesterolemia. This drug participated in phase III clinical trial; however, information about the further development of this drug is not available.
Status:
Investigational
Source:
NCT00050882: Phase 2 Gastroparesis
(2003)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.